[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537555":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":56,"collaborators":59,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":18,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":18,"overallStatus":40,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Xinqiao Hospital of Chongqing","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Test group","EXPERIMENTAL","Thalidomide+cetuximab+FOLFOX\u002FFOLFIRI",[13],"Drug: Thalidomide+cetuximab+FOLFOX\u002FFOLFIRI",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","cetuximab+FOLFOX\u002FFOLFIRI",null,[20],{"type":21,"name":11,"description":11,"armGroupLabels":22,"otherNames":18},"DRUG",[9],[24],{"name":25,"affiliation":26,"role":27},"rui kong, doctor","Chongqing Medical University","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":18,"email":33},"Jianguo Sun, doctor","CONTACT","023-68774490","sunjianguo@tmmu.edu.cn",{"name":25,"role":31,"phone":35,"phoneExt":18,"email":36},"15823688918","kongruiok@163.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"the second affiliated hospital of Army medical university","RECRUITING","Chongqing","Chongqing Municipality","400037","China","CN",{"type":47,"coordinates":48},"Point",[49,50],106.55771,29.56026,{"lat":50,"lon":49},[53],{"name":54,"role":31,"phone":32,"phoneExt":18,"email":55},"jianguo Sun, Phd","sunjg09@aliyun.com",{"type":27,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Jianguo Sun","Deputy director of oncology department, Clinical Professor",[60],{"name":26,"class":6},"100537555","phase-2-thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer-100537555",false,"NCT06279351","Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue\u002Fcytology and genetic testing;\n2. Physical state is good: PS 0-2;\n3. Expected survival of more than 3 months;\n4. Aged 18-75 years old;\n5. Have not received systematic chemotherapy before;\n6. Did not receive cetuximab treatment;\n7. Liver, kidney and bone marrow functions are basically normal;\n8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;\n9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunction of vital organs (heart, liver, kidney);\n2. Patients with other malignant tumors;\n3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);\n4. In the active phase of acute or chronic infectious diseases;\n5. People with a clear history of drug allergy or allergic constitution;\n6. Patients participating in other clinical trials;\n7. Other conditions in which the patient was considered inappropriate to participate in the study.","ALL","18 Years","75 Years",{"count":71,"type":72},96,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.\n2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.",[65],"2025-07-11",{"date":80,"type":81},"2025-07-14","ACTUAL",{"date":83,"type":81},"2024-08-11",{"date":85,"type":72},"2025-12-31",{"name":5,"class":6},1]